Old Drugs as New Treatments for Neurodegenerative Diseases - PubMed (original) (raw)

Review

Old Drugs as New Treatments for Neurodegenerative Diseases

Fernando Durães et al. Pharmaceuticals (Basel). 2018.

Abstract

Neurodegenerative diseases are increasing in number, given that the general global population is becoming older. They manifest themselves through mechanisms that are not fully understood, in many cases, and impair memory, cognition and movement. Currently, no neurodegenerative disease is curable, and the treatments available only manage the symptoms or halt the progression of the disease. Therefore, there is an urgent need for new treatments for this kind of disease, since the World Health Organization has predicted that neurodegenerative diseases affecting motor function will become the second-most prevalent cause of death in the next 20 years. New therapies can come from three main sources: synthesis, natural products, and existing drugs. This last source is known as drug repurposing, which is the most advantageous, since the drug’s pharmacokinetic and pharmacodynamic profiles are already established, and the investment put into this strategy is not as significant as for the classic development of new drugs. There have been several studies on the potential of old drugs for the most relevant neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

Keywords: Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; amyotrophic lateral sclerosis; drug repurposing; multiple sclerosis; neurodegenerative diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Figure 1

Summary of the diseases and repurposed drugs presented in this review.

Figure 2

Figure 2

Structure of drugs 1–29 (*) Preclinical Studies; (**) Under clinical studies; (***) Clinically approved.

Figure 2

Figure 2

Structure of drugs 1–29 (*) Preclinical Studies; (**) Under clinical studies; (***) Clinically approved.

Figure 2

Figure 2

Structure of drugs 1–29 (*) Preclinical Studies; (**) Under clinical studies; (***) Clinically approved.

Figure 2

Figure 2

Structure of drugs 1–29 (*) Preclinical Studies; (**) Under clinical studies; (***) Clinically approved.

Figure 3

Figure 3

Structure of drugs 30–36 (*) Preclinical Studies; (**) Under clinical studies; (***) Clinically approved.

Figure 4

Figure 4

Structure of drugs 37–43 (*) Preclinical Studies; (**) Under clinical studies; (***) Clinically approved.

Figure 5

Figure 5

Structure of drugs 44–48 (*) Preclinical Studies; (**) Under clinical studies; (***) Clinically approved.

Figure 6

Figure 6

Structure of drugs 49–54 (*) Preclinical Studies; (**) Under clinical studies; (***) Clinically approved.

Similar articles

Cited by

References

    1. Ashburn T.T., Thor K.B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 2004;3:673–683. doi: 10.1038/nrd1468. - DOI - PubMed
    1. Doan T.L., Pollastri M., Walters M.A., Georg G.I. Chapter 23—The future of drug repositioning: Old drugs, new opportunities. In: Macor J.E., editor. Annual Reports in Medicinal Chemistry. Volume 46. Academic Press; Waltham, MA, USA: 2011. pp. 385–401.
    1. Fava M. The promise and challenges of drug repurposing in psychiatry. World Psychiatry. 2018;17:28–29. doi: 10.1002/wps.20481. - DOI - PMC - PubMed
    1. Richardson P., Hideshima T., Anderson K. Thalidomide: Emerging role in cancer medicine. Annu. Rev. Med. 2002;53:629–657. doi: 10.1146/annurev.med.53.082901.104043. - DOI - PubMed
    1. Sleire L., Forde H.E., Netland I.A., Leiss L., Skeie B.S., Enger P.O. Drug repurposing in cancer. Pharmacol. Res. 2017;124:74–91. doi: 10.1016/j.phrs.2017.07.013. - DOI - PubMed

Publication types

LinkOut - more resources